Microbiome is not linked to clinical disease severity of familial Mediterranean fever in an international cohort of children.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
Historique:
received: 06 11 2020
accepted: 01 02 2021
pubmed: 13 7 2021
medline: 12 10 2021
entrez: 12 7 2021
Statut: ppublish

Résumé

The severity of familial Mediterranean fever (FMF) may vary in different areas, suggesting a role for environmental factors. We analysed the composition of gut microbiota among children with FMF and healthy controls from Turkey and the USA and determined its effect on disease severity. Children with FMF with pathogenic MEFV mutations and healthy controls from Turkey and the USA were enrolled. FMF disease activity was evaluated with the Autoinflammatory Disease Activity Index (AIDAI). Gut bacterial diversity was assessed by sequencing 16S rRNA gene libraries. We included 36 children from Turkey (28 patients with FMF, 8 healthy controls), and 21 patients and 6 controls from the USA. In the Turkish group, 28.6% of patients had severe disease, while 13.3% of US group patients had severe disease. As expected, we observed substantial differences between the gut microbiota of children from the two geographic regions, with Turkish patients and controls exhibiting higher relative abundances of Bacteriodia, while US patients and controls exhibited higher relative abundances of Clostridia. Alpha- and betadiversity did not differ significantly between FMF patients and controls, and neither was predictive of disease severity within each geographic region. We observed differences between FMF patients and controls in the relative abundance of some bacterial taxa at the amplicon sequence variant (ASV) level, but these differences received mixed statistical support. Among an international cohort of children with FMF, we did not find a strong effect of gut microbiota composition on disease severity. Other environmental or epigenetic factors may be operative.

Identifiants

pubmed: 34251310
pii: 16649
doi: 10.55563/clinexprheumatol/olvbyd
doi:

Substances chimiques

MEFV protein, human 0
Pyrin 0
RNA, Ribosomal, 16S 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102-108

Auteurs

Seza Ozen (S)

Department of Paediatric Rheumatology, Hacettepe University Faculty of Medicine in Ankara, Turkey. sezaozen@gmail.com.

Holly L Lutz (HL)

Department of Paediatrics, University of California San Diego, La Jolla, CA, and Scripps Institution of Oceanography, University of California San Diego, La Jolla, CA, USA.

Vanessa M Rivera (VM)

Division of Rheumatology at CHLA, Los Angeles, CA, USA.

Andreas Reiff (A)

Division of Rheumatology at CHLA, Los Angeles, CA, USA.

Ezgi Deniz Batu (ED)

Department of Paediatric Rheumatology, Hacettepe University Faculty of Medicine in Ankara, Turkey.

Edwin Anderson (E)

Program in Rheumatology, Division of Immunology, Boston Children's Hospital, Boston, MA, USA.

Mariana Salas Garcia (M)

Department of Paediatrics, University of California San Diego, La Jolla, CA, and Scripps Institution of Oceanography, University of California San Diego, La Jolla, CA, and Division of Rheumatology at CHLA, Los Angeles, CA, USA.

Grace Aldrovandi (G)

Division of Rheumatology at CHLA, Los Angeles, CA, USA.

Tayfun Hilmi Akbaba (TH)

Department of Medical Biology, Hacettepe University, Ankara, Turkey.

İlker Pazarbasi (İ)

Department of Nutrition and Dietetics, Hacettepe University, Ankara, Turkey.

Yelda Bilginer (Y)

Department of Paediatric Rheumatology, Hacettepe University Faculty of Medicine in Ankara, Turkey.

Ayse Balat (A)

Division of Nephrology and Rheumatology, Istanbul Aydin University, Istanbul, Turkey.

Banu Balci-Peynircioglu (B)

Department of Medical Biology, Hacettepe University, Ankara, Turkey.

Jack A Gilbert (JA)

Department of Paediatrics, University of California San Diego, La Jolla, CA, and Scripps Institution of Oceanography, University of California San Diego, La Jolla, CA, and Division of Rheumatology at CHLA, Los Angeles, CA, USA.

Fatma Dedeoglu (F)

Program in Rheumatology, Division of Immunology, Boston Children's Hospital, Boston, MA, USA.

Jonathan S Hausmann (JS)

Program in Rheumatology, Division of Immunology, Boston Children's Hospital, Boston, MA, and Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH